As described elsewhere 84, 98 and illustrated in Figure 4, epigenetically targeting miR-21 85, 91, miR-192 86, 94, miR-433 95, miR-29 96, 97 and miR-200 family 88, Erbb4-IR 102, LRNA9884 104, 105, Arid2-IR 103, and Lnc-TSI 106 have been shown to be a novel and specific anti-fibrosis and anti-inflammation therapy for kidney diseases. Here, INSR is linked to kidney disorder.